Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Characterization of the Microbiome to Predict Complications in Chronic Kidney Disease and End Stage Kidney Disease Patients

Clinical Trial Details

In this protocol, we plan to prospectively recruit subjects with chronic kidney disease or end stage kidney disease on dialysis. We will obtain stool, blood, urine (if possible), and peritoneal fluid (if on peritoneal dialysis) from the subjects on a regular basis and we will correlate whether the microbiome in these biospecimens are associated with and/or predictive of bacteremia and other complications in chronic kidney disease and end stage kidney disease. Recent evidence suggests that the microbiota may be related to infectious complications like bacteremia 

Key Eligibility: 

Either male or female, ages 18 to 95, chronic kidney disease (with estimated GFR; 60 ml/min/1.73 m2). 

Study contact by location

Upper East Side - Manhattan


Emmanuel Edusei
(212) 746-6112

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:



Open to Enrollment

Age Group